On the stock market since 2025, it operates in the world of health and science. It has 574 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 198% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades below its recent peak — about 8% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 228% a year on average.
The company sells $980.7M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $405.4M against $980.7M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, AAPGV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AAPGV has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.